$13.51+0.22 (+1.66%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Trevi Therapeutics (TRVI) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+108.8%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲10.8%
−42.8
FY21→FY25CAGR —
Free cash flow ($M)▼10.0%
−42.1
FY21→FY25CAGR —
Diluted EPS▲31.9%
−0.32
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+108.8%
64.5mn → 134.7mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.
Capex
$12.0K
−65.7% YoY in FY25.
Returns vs FCF
n/m
$0.8M returned vs $−42.1M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 50,350.0 | 33,478.0 | 39,377.0 | 23,683.0 | 19,834.0 | 22,984.0 | ▼15.0% | +9.9% |
Selling, general & admin | 19,777.0 | 15,850.0 | 12,147.0 | 10,240.0 | 10,073.0 | 9,492.0 | ▲30.5% | +13.7% |
Total operating expenses | 70,127.0 | 49,328.0 | 51,524.0 | 33,923.0 | 29,907.0 | 32,476.0 | ▼4.3% | +11.0% |
Operating incomefeeds ROC rank | −70,127.0 | −49,328.0 | −51,524.0 | −33,923.0 | −29,907.0 | −32,476.0 | ▲4.3% | — |
Other income, net | 9,295.0 | 6,505.0 | 3,583.0 | 4,826.0 | 719.0 | −1,485.0 | — | — |
Pretax income | −60,832.0 | −42,823.0 | −47,941.0 | −29,097.0 | −29,188.0 | −33,961.0 | ▲10.7% | — |
Income tax | −75.0 | −64.0 | −30.0 | −32.0 | −36.0 | −21.0 | ▼113.3% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −60,757.0 | −42,759.0 | −47,911.0 | −29,065.0 | −29,152.0 | −33,940.0 | ▲10.8% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.39 | −0.32 | −0.47 | −0.29 | −0.45 | −1.49 | ▲31.9% | — |
Diluted shares (mn) | 159.73 | 134.75 | 101.97 | 99.03 | 64.54 | 22.84 | ▲32.1% | +55.8% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

